Liver Transplant for Nonhepatocellular Carcinoma Tumors: A Review of Expanding Indications in Nontraditional Transplant Oncology

Abstract

Liver transplantation (LT) is a life-saving procedure most well-known in the curative treatment of cirrhosis or end-stage liver disease. The approach is also well established for hepatocellular carcinoma (HCC) within Milan or other similar criteria. However, LT is increasingly utilized as the treatment for other primary and secondary liver cancers, including cholangiocarcinoma, colorectal cancer liver metastasis, neuroendocrine tumor, and angiosarcoma. We aim to review indications for LT for non-HCC hepatic malignancies.

Keywords

liver transplantation - transplant oncology - selection criteria

Authors' Contributions

Concept generation: C.J.W., S.F., F.A.

Literature review: C.J.W., S.F.

Manuscript drafting: C.J.W., S.F., F.A.

Manuscript editing and critical review: All authors.

^* Denotes equal contribution.

Publikationsverlauf

Eingereicht: 03. März 2024

Angenommen: 06. August 2024

Artikel online veröffentlicht:
20. Dezember 2024

• References

• 1 Kwong AJ, Ebel NH, Kim WR. et al. OPTN/SRTR 2021 Annual Data Report: Liver. Am J Transplant 2023; 23 (2, Suppl 1): S178-S263
• 2 Organ Procurement and Transplantation Network (OPTN). National Data. U.S. Department of Health and Human Services; 2023
• 3 Mahmud N. Selection for liver transplantation: indications and evaluation. Curr Hepatol Rep 2020; 19 (03) 203-212
• 4 Wehrle CJ, Zhang M, Khalil M. et al Impact of back-to-base normothermic machine perfusion on complications and costs: a multi-center, real-world risk-matched analysis. Ann Surg 2024; 280 (02) 300-310
• 5 Wehrle CJ, Hong H, Gross A. et al The impact of normothermic machine perfusion and acuity circles on waitlist time, mortality and cost in liver transplantation: a multicenter experience. Liver Transpl 2024;
• 6 The Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer, N.C.I.S. Program, Editor; 2023
• 7 Watson J, Hydon K, Lodge P. Primary and secondary liver tumours. InnovAiT 2016; 9 (08) 477-482
• 8 Wehrle CJ, Kusakabe J, Akabane M. et al Expanding selection criteria in deceased donor liver transplantation for hepatocellular carcinoma: long-term follow-up of a national registry and 2 transplant centers. Transplantation 2024;
• 9 Kim SH, Navot B, Guniganti P, Gavlin A, Hecht EM, Kierans AS. Liver transplant for nonhepatocellular malignancies: a review for radiologists. AJR Am J Roentgenol 2022; 219 (04) 590-603
• 10 Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: indications, limitations, and analysis of the current literature. Liver Transpl 2010; 16 (08) 930-942
• 11 Dueland S, Smedman TM, Syversveen T, Grut H, Hagness M, Line PD. Long-term survival, prognostic factors, and selection of patients with colorectal cancer for liver transplant: a nonrandomized controlled trial. JAMA Surg 2023; 158 (09) e232932-e232932
• 12 Chávez-Villa M, Ruffolo LI, Al-Judaibi BM. et al. The high incidence of occult carcinoma in total hepatectomy specimens of patients treated for unresectable colorectal liver metastases with liver transplant. Ann Surg 2023; 278 (05) e1026-e1034
• 13 Hernandez-Alejandro R, Ruffolo LI, Sasaki K. et al. Recipient and donor outcomes after living-donor liver transplant for unresectable colorectal liver metastases. JAMA Surg 2022; 157 (06) 524-530
• 14 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 15 Hagness M, Foss A, Line PD. et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013; 257 (05) 800-806
• 16 Dueland S, Syversveen T, Solheim JM. et al. Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg 2020; 271 (02) 212-218
• 17 Wehrle CJ, Raj R, Aykun N. et al. Liquid biopsy by ctDNA in liver transplantation for colorectal cancer liver metastasis. J Gastrointest Surg 2023; 27 (07) 1498-1509
• 18 Rajendran L, Claasen MP, McGilvray ID. et al. Toronto management of initially unresectable liver metastasis from colorectal cancer in a living donor liver transplant program. J Am Coll Surg 2023; 237 (02) 231-242
• 19 Sasaki K, Ruffolo LI, Kim MH. et al. The current state of liver transplantation for colorectal liver metastases in the United States: a call for standardized reporting. Ann Surg Oncol 2023; 30 (05) 2769-2777
• 20 Wehrle CJ, Fujiki M, Schlegel A. et al Update to ‘A contemporary systematic review on liver transplantation for unresectable liver metastasis of colorectal cancer’. Ann Surg Oncol 2024; 31 (02) 697-700 . Epub 2023 Nov 23. PMID: 37996635
• 21 Grut H, Line PD, Syversveen T, Dueland S. Metabolic tumor volume predicts long-term survival after transplantation for unresectable colorectal liver metastases: 15 years of experience from the SECA study. Ann Nucl Med 2022; 36 (12) 1073-1081
• 22 Wehrle CJ, Fujiki M, Schlegel A. et al Intensive locoregional therapy before liver transplantation for colorectal cancer liver metastasis: A novel pretransplant protocol. Liver Transpl 2024; 30 (12) 1238-1249
• 23 Wehrle CJ, Raj R, Aykun N. et al. Circulating tumor DNA in colorectal cancer liver metastasis: analysis of patients receiving liver resection and transplant. JCO Clin Cancer Inform 2023; 7: e2300111
• 24 Kotani D, Oki E, Nakamura Y. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023; 29 (01) 127-134
• 25 Tie J, Cohen JD, Lahouel K. et al; DYNAMIC Investigators. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022; 386 (24) 2261-2272
• 26 Bonney GK, Chew CA, Lodge P. et al. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol 2021; 6 (11) 933-946
• 27 Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 2016; 21 (05) 594-599
• 28 Boberg KM, Lind GE. Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol 2011; 25 (06) 753-764
• 29 Sapisochin G, Javle M, Lerut J. et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104 (06) 1125-1130
• 30 Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69 (08) 1633-1637
• 31 Robles R, Figueras J, Turrión VS. et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004; 239 (02) 265-271
• 32 Safarpour AR, Askari H, Ejtehadi F. et al. Cholangiocarcinoma and liver transplantation: What we know so far?. World J Gastrointest Pathophysiol 2021; 12 (05) 84-105
• 33 Darwish Murad S, Kim WR, Harnois DM. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143 (01) 88-98.e3 , quiz e14
• 34 Darwish Murad S, Kim WR, Therneau T. et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 2012; 56 (03) 972-981
• 35 Lehrke HD, Heimbach JK, Wu TT. et al. Prognostic significance of the histologic response of perihilar cholangiocarcinoma to preoperative neoadjuvant chemoradiation in liver explants. Am J Surg Pathol 2016; 40 (04) 510-518
• 36 Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol 2020; 72 (02) 364-377
• 37 Lunsford KE, Javle M, Heyne K. et al; Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC). Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 2018; 3 (05) 337-348
• 38 Spolverato G, Pawlik TM. Liver-directed therapies: surgical approaches, alone and in combination with other interventions. American Society of Clinical Oncology Educational Book 2014; (34) 101-110
• 39 Jain A, Borad MJ, Kelley RK. et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precis Oncol 2018; 2: 1-12
• 40 Churi CR, Shroff R, Wang Y. et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014; 9 (12) e115383
• 41 Frilling A, Modlin IM, Kidd M. et al; Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15 (01) e8-e21
• 42 Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
• 43 Gedaly R, Daily MF, Davenport D. et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011; 146 (08) 953-958
• 44 Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I. et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review. Surgery 2017; 162 (03) 525-536
• 45 Kim J, Zimmerman MA, Hong JC. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. J Gastrointest Oncol 2020; 11 (03) 601-608
• 46 Olausson M, Friman S, Herlenius G. et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl 2007; 13 (03) 327-333
• 47 HRA Administration, OPTN/SRTR 2020 Annual Data Report: Liver. US Department of Health and Human Services; 2020
• 48 Alrenga DP. Primary angiosarcoma of the liver. Review article. Int Surg 1975; 60 (04) 198-203
• 49 Levy DW, Rindsberg S, Friedman AC. et al. Thorotrast-induced hepatosplenic neoplasia: CT identification. AJR Am J Roentgenol 1986; 146 (05) 997-1004
• 50 Fracanzani AL, Conte D, Fraquelli M. et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33 (03) 647-651
• 51 Falk H, Thomas LB, Popper H, Ishak KG. Hepatic angiosarcoma associated with androgenic-anabolic steroids. Lancet 1979; 2 (8152) 1120-1123
• 52 Locker GY, Doroshow JH, Zwelling LA, Chabner BA. The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature. Medicine (Baltimore) 1979; 58 (01) 48-64
• 53 Maluf D, Cotterell A, Clark B, Stravitz T, Kauffman HM, Fisher RA. Hepatic angiosarcoma and liver transplantation: case report and literature review. Transplant Proc 2005; 37 (05) 2195-2199
• 54 Orlando G, Adam R, Mirza D. et al. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation – the European Liver Transplant Registry experience. Transplantation 2013; 95 (06) 872-877
• 55 Lerut JP, Orlando G, Adam R. et al. The place of liver transplantation in the treatment of hepatic epithelioid hemangioendothelioma. Ann Surg 2007; 246 (06) 949-957
• 56 Merriam P, Nathenson MJ. Liver transplantation for hepatic epithelioid hemangioendothelioma. Cancer 2021; 127 (20) 3714-3716
• 57 Lai Q, Feys E, Karam V. et al; European Liver Intestine Transplant Association (ELITA). Hepatic epithelioid hemangioendothelioma and adult liver transplantation: proposal for a prognostic score based on the analysis of the ELTR-ELITA registry. Transplantation 2017; 101 (03) 555-564
• 58 Rodriguez JA, Becker NS, O'Mahony CA, Goss JA, Aloia TA. Long-term outcomes following liver transplantation for hepatic hemangioendothelioma: the UNOS experience from 1987 to 2005. J Gastrointest Surg 2008; 12 (01) 110-116
• 59 Mehrabi A, Kashfi A, Fonouni H. et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006; 107 (09) 2108-2121
• 60 Solheim JM, Dueland S, Line PD, Hagness M. Transplantation for nonresectable colorectal liver metastases - long term follow-up of the first prospective pilot study. Ann Surg 2023; 278 (02) 239-245
• 61 Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230 (03) 309-318 , discussion 318–321
• 62 OPTN/UNOS Liver and Intestinal Organ Transplantation Committee. Briefing Paper: Liver Review Board Guidance Documents. 2017